About Us

What we do

FDNA® develops innovative, effective and affordable rare disease mobile health solutions, supporting better referrals, screening, diagnostics, monitoring and administration of therapeutic treatments for large undiagnosed patient populations. Our mission is to save lives and improve the quality of life of rare disease patients, by promoting earlier and more accurate diagnostics. Visit our resource center to learn more about dysmorphic symptoms of genetic disorders.


Our technology is utilized as a decision support tool for clinical geneticist, as well as a platform that facilitate medical and pharmaceutical research. Click here to read more about our solutions.

Who we are

Our Scientific Advisory Board

Dr. Michael R. Hayden, CM OBC FRSC
Dr. Hayden is the President of Global R&D and Chief Scientific Officer of Teva Pharmaceutical Industries and the Editor in Chief of the scientific journal - Clinical Genetics. His work in genetics and personalized medicine is internationally renowned, and he is one of the world’s leading experts in human genetics. Currently, he is Killam Professor of Medical Genetics at the University of British Columbia, and Canada Research Chair in Human Genetics and Molecular Medicine. He is also the founder and Director/Senior Scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia. Dr. Hayden was awarded the Canada Gairdner Wightman award, recognizing him as a physician-scientist who has demonstrated outstanding leadership in medicine and medical science; in 2010, he was awarded the Order of Canada, which is the highest honour that Canada can give its citizens for exceptional achievement, merit or service; in 2008 he was named Canada's Health Researcher of the Year and in 1998 received the Distinguished Scientist Award of the Canadian Society of Clinical Investigation.

Prof. Mordechai (Motti) Shohat, MD
Prof. Shohat is the head of the genetic department in Schneider and Rabin Hospitals in Israel, and is a world renowned expert in medical genetics with 248 original research articles to his credit. He has co-authored and edited two books, and received numerous personal awards for his achievements in genetics research. For several decades he has served as professor of pediatrics and medical genetics at Tel Aviv University and Director of the Rafael Recanathi institute for Medical Genetics. Prof. Shohat is a member of the Israeli, American and European Societies of Medical Genetics, as well as of the National Counseling Committee of the Ministry of Health for OB/GYN and Genetics.

Ms. Vivian J. Weinblatt, MS, CGC
Ms. Weinblatt, the former president of the National Society of Genetic Counselors and the Genetic Counseling Foundation, is a certified genetic counselor with over 20 years of clinical experience in multiple settings. Ms. Weinblatt is currently an adjunct professor at Arcadia University’s Genetic Counseling Program. She has published book chapters on the topics of genetic counseling and multiple gestations. Ms. Weinblatt obtained her undergraduate degree from Cornell University in Human Development and Family Studies, and her Master’s degree in Genetic Counseling from the University of California, Berkeley. Ms. Weinblatt is certified by the American Board of Medical Genetics, and is a Charter member of the American Board of Genetic Counseling.

Our Business Advisory Board

Mr. Israel Makov
Mr. Makov is Chairman of Sun Pharmaceutical Industries Limited; Given Imaging; BioLight Israeli Life Sciences Investments Ltd.; Micromedic Technologies Ltd. & Eltav. He is also the former Chairman of Netafim and the former President & CEO of Teva Pharmaceutical Industries Ltd. He led Teva's global expansion and under his leadership the company became the undisputed global leader in the generic pharmaceutical industry. Prior to joining Teva, Mr. Makov led a number of companies in various industries, and founded Israel’s first biotech company, Interpharm, which went public in the US. He is a member of the Board of Directors of the Israel National Nanotechnology Initiative, an initiative he also helped found. He is a member of the Executive Board & Management Committee of the Weizmann Institute of Science, on the Board of Governors of the Technion – Israel Institute of Technology, Chairman of the Board of the Institute for Policy and Strategy at the Interdisciplinary Center of Herzliya, President of the Friends of Schneider Children’s Medical Center of Israel and Chairman of the Friends of Gesher Theatre, one of Israel’s leading theaters. Mr. Makov has a B.Sc. in Agriculture and an M.Sc. in Economics from the Hebrew University in Jerusalem.

Mr. Fredric Price
Mr. Price is Executive Chairman of the Board of Directors of Chiasma, having served as its Chairman and CEO from 2008 to 2013. In addition, he is Chairman of BioBlast and a member of the Board of Directors of Celsus Therapeutics. Previously, he was Executive Chairman of the Board of Directors of Omrix Biopharmaceuticals, a member of the Board of Directors of Enobia Pharma, a member of the Board of Directors of Pharmasset, Executive Chairman of the Board of Directors of Peptimmune, Chairman of the Board of Directors and CEO of BioMarin Pharmaceutical and CEO and a member of the Board of Directors of Applied Microbiology. His earlier experience includes having been Vice President of Finance and Administration and CFO of Regeneron Pharmaceuticals, the founder of the strategy consulting firm RxFDP and Vice President of Pfizer Pharmaceuticals with both line and staff responsibilities. Mr. Price is a co-inventor of 13 issued US patents. He received a BA from Dartmouth College and an MBA from the Wharton School of the University of Pennsylvania.

Mr. John Porter
Mr. Porter is Chairman of Sinocare Group, which owns and operates hospitals in the PRC.  Mr. Porter has had a history of involvement with the Life Sciences, helping to found Natus Medical and serving for 5 years as a director of Ivax Corp now part of Teva. Mr. Porter holds degrees from the Universities of Oxford, Paris and Stanford.  He serves on the Board of Advisors to the Said Business School, Oxford and has served two terms on the Board of Advisors to Stanford Business School.


Our Management Team
 

Mr. Moti Shniberg, Co-Founder & Chairman
Mr. Shniberg is a serial entrepreneur with over a decade of experience founding and managing global businesses in myriad industries. Mr. Shniberg is the chairman of several companies, including among others, Face.com, the leading image auto-tagging service provider and developer of proprietary face-recognition technology, Artist Pension Trust (APT) and Mutual Art.

 

Mr. Dekel Gelbman, LL.B, MBA, CEO
Mr. Gelbman has over a decade of experience in legal counseling, regulatory compliance and business development in the venture capital industry, both in private and publicly traded companies. Mr. Gelbman previously worked for the leading U.S. based law firm Skadden Arps. Mr. Gelbman holds an LL.B and an MBA in finance.

Prof. Lior Wolf, Ph.D, Co-Founder & Chief Scientist
Prof. Lior Wolf is a faculty member at the School of Computer Science at Tel-Aviv University. Previously, he was a post-doctoral associate in the center for biological & computer learning at MIT. Prof. Wolf’s research and academic papers received international awards and prizes, as well as grants and scholarships. Prof. Wolf has extensive experience in forming, advising and heading R&D in a number of successful businesses in the computer vision field. 

Prof. Lina Basel, MD, Ph.D, Medical Director
Prof. Basel is head of the children genetic clinic and head of the genetic service at Schneider Hospital in Israel. Prof. Basel has more than a decade of experience with genetic practice and child development. She has also co-authored numerous research articles together with Prof. Shohat and received numerous personal awards for her achievements in genetics research. Prof. Basel also serves as a professor of human genetics and pediatrics at Tel Aviv University and is frequently invited to speake in international conferences and conventions.

Dr. Yakir Rottenberg, MD, MPH, Director of Clinical Studies & Medical Content
Dr. Rottenberg is an expert in Oncology from the Sharett Institute of Oncology and Geriatric department, Hadassah - Hebrew University Medical Center. His research includes genetic and environment testing as risk factors for illness and mortality. Dr. Rottenberg previously headed the project of forming a national data base for mortality risk factors. Dr. Rottenberg holds a master in public health in biostatistics and epidemiology from the Hebrew University in Jerusalem.

Dr. Leonid Karlinsky, Ph.D, Director of R&D
Dr. Karlinsky has extensive hands-on experience in leading R&D projects and academic research in the field computer vision. Dr. Karlinsky holds a PhD in computer vision from the Weizmann Institute of Science in Israel.